Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Genmab A/S
  6. News
  7. Summary
    GMAB   DK0010272202

GENMAB A/S

(GMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Genmab A/S : Morgan Stanley Downgrades Genmab to Underweight from Equalweight, Keeps $37 Price Target

09/07/2021 | 09:52am EST


ę MT Newswires 2021
All news about GENMAB A/S
12/02Genmab A/S has published its Articles of Association
AQ
12/01Berenberg Initiates Coverage on Genmab With Sell Rating
MT
11/22GENMAB A/S : Grant of Restricted Stock Units to Board Members and Employees and Grant of W..
PU
11/22Transactions with shares and linked securities in Genmab A/S made by managerial employe..
AQ
11/22Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to..
AQ
11/18Genmab A/S has published its Articles of Association
AQ
11/16Capital Increase in Genmab as a Result of Employee Warrant Exercise
AQ
11/16GENMAB A/S : Capital Increase in Genmab as a Result of Employee Warrant Exercise - Form 6-..
PU
11/10Genmab Investor Presentation - November 2021
PU
11/10Tranche Update on Genmab A/S's Equity Buyback Plan announced on March 1, 2021.
CI
More news
Analyst Recommendations on GENMAB A/S
More recommendations
Financials
Sales 2021 8 275 M 1 259 M 1 259 M
Net income 2021 2 852 M 434 M 434 M
Net cash 2021 18 725 M 2 849 M 2 849 M
P/E ratio 2021 60,4x
Yield 2021 -
Capitalization 172 B 26 204 M 26 167 M
EV / Sales 2021 18,5x
EV / Sales 2022 14,0x
Nbr of Employees 1 136
Free-Float 94,9%
Chart GENMAB A/S
Duration : Period :
Genmab A/S Technical Analysis Chart | GMAB | DK0010272202 | MarketScreener
Technical analysis trends GENMAB A/S
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 2 629,00 DKK
Average target price 2 816,96 DKK
Spread / Average Target 7,15%
EPS Revisions
Managers and Directors
Jan G. J. van de Winkel President & Chief Executive Officer
Anthony Pagano Chief Financial Officer & Executive Vice President
Deirdre P. Connelly Chairman
Tahamtan Ahmadi Chief Medical Officer & Executive Vice President
Anthony Mancini Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
GENMAB A/S6.74%26 204
GILEAD SCIENCES, INC.19.65%87 443
BIONTECH SE258.12%70 510
REGENERON PHARMACEUTICALS35.38%68 384
WUXI APPTEC CO., LTD.24.26%64 686
VERTEX PHARMACEUTICALS-12.58%52 531